Let’s play a little game. Let’s say that you’re the CSO at a cancer pharma company, and you have to choose a target to go after. Here’s a gene – high expression is associated with poor prognosis in brain cancer. Looks like a good candidate for an inhibitor right?

I integrate and annotate 75 AML biopsies in part 2 of my 2024 single-cell guide. Custom label transfer, nuanced integration with hyperparameter tuning, avoiding pitfalls in analysis, etc. It's long, but one of my favorite videos so far. youtu.be/FqG_O12oWR4

🌟 New paper alert 🌟 Especially in these difficult times, very happy and proud to share our new study: Mapping the tumor stress network reveals dynamic shifts in the stromal oxidative stress response cell.com/cell-reports/f…

Natural killer cells show their cancer-fighting worth nature.com/articles/d4158… Wonderful commentary on the state of NK cell therapy!

This vial of medicine may look unremarkable, but ipilimumab was the first treatment of any type with the ability to offer the hope of survival for patients with metastatic melanoma. Learn more: nobelprize.org/prizes/medicin…

Now online in Cancer Discovery: Iron-(Fe3+) dependent Reactivation of #Telomerase Drives #ColorectalCancer - by Raghuvaran Shanmugam, Prativa Majee, Wei Shi, Iain Tan, NCCS/GIS/Duke-NUS/STCC, Vinay Tergaonkar, et al doi.org/10.1158/2159-8… A*STAR Research Genome Institute of Singapore NUS

Many congratulations to our Dr. Sunil Acharya sunil acharya for his exciting research on CD70-targeting CAR NK cells, published in Cancer Discovery! Sunil and his co-authors showed that the incorporation of CD28 costimulation, which is normally absent in NK cells, in the CAR

A recent study led by @rondepinho identified a molecule compound that restores physiological levels of telomerase reverse transcriptase (TERT), which is repressed during aging. What this could mean for age-related diseases: bit.ly/4eBaVKU #EndCancer

We have vastly expanded our database of PhD fellowships. For each of the 189 funding opportunities, we provide description, link, deadline, amount, and eligibility requirements. Download for free the database here: research.jhu.edu/rdt/funding-op…

Recently, the Tanoto Foundation made a generous pledge to support cell therapy discovery and innovation research, led by our Dr. Katy Rezvani and her team. Read more: bit.ly/4d9hoLO Katy Rezvani, M.D., Ph.D #EndCancer

Two impressive nature papers on the genomics of colon cancer, linking with outcomes, identify new mutations, likely role of diet and strengthen the case for sequencing to be used in medical practice nature.com/articles/s4158… nature.com/articles/s4158…

Delighted to share our latest research published in Cancer Cell Cell. Our study shows that intratumoral administration of IL-21 engineered NK cells resulted in strong and sustained antitumor activity against glioblastoma compared to IL-15 NK cells, which carried significant

A correlation between increased cardiorespiratory fitness (V02 max) and protection from brain aging (reflected by less demyelination) pnas.org/doi/epub/10.10… PNASNews Mustapha BOUHRARA

AI can be used to make convincing looking fake data. There is no way we can distinguish real from fake anymore. It is safe to assume that genAI has already resulted in many fake papers. Scientific publishing is not prepared for this.

Great study led by Kate Hockemeyer - strengthening emerging importance of stress signatures in dysfunctional TILs

📢 Hot off the press! CAFs are major regulators of the immune tumor microenvironment. In our new review we dissect a fascinating aspect of this regulation: CAF-induced physical constraints controlling T cell state and localization in solid tumours nature.com/articles/s4156…

Excited to share our manuscript published in Science Translational Medicine, where we describe a novel NK immune evasion strategy in AML. We found that #BATF is a key transcription factor driving epigenetic reprogramming in NK cells in AML. This TF is induced by the canonical TGF-β/SMAD pathway and

Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial By Myriam Chalabi & colleagues in Nature Medicine nature.com/articles/s4159… Not sure much more mind blowing the pathologic response or OS in this setting can be! #ESMO24

Cancer in the young is on the rise worldwide, but the basis for this is not known. A new review covers it well, open-access cell.com/cell-reports-m… Alberto Bardelli Gianluca Mauri Cell Reports Medicine

Fantastic review by Ruth Shouval lab; regulation of T-cell infiltration and activity in solid tumors by CAFs